The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing and analyte characterization from a single cell. Such polynucleotide processing may be useful for a variety of applications, including cell lineage analysis. Cell lineage analysis may comprise the use of one or more lineage tracing nucleic acid molecules. The disclosed methods may comprise using a lineage tracing nucleic acid molecule to identify a biological particle with one or more progenitor cells.

An object of the present invention is to provide a highly sensitive immunoanalysis method and analysis apparatus. The invention relates to an analysis method and an analysis apparatus which are constituted in such a way that a component to be measured is reacted with capture component specifically reacting thereto and the reactant is labeled when the component to be measured is present and which are characterized by analyzing the component to be measured with single-molecule sensitivity and resolution by arranging the labeled reactant in a spatially separated certain position and detecting the label of the labeled reactant.

Disclosed herein are devices and methods that use aqueous two phase systems and lateral flow assays to detect target analytes in a sample. These devices and methods may be used to diagnose a disease or condition in a biological sample, such as blood or serum. In addition, these devices and methods may be used to detect allergens in a food samples or contaminants, such as environmental toxins, in water samples. Device and kit components may be conveniently assembled in a portable container and are amenable to actuation in most settings. The devices are simple to use, requiring a non-trained operator to simply add the sample to the device. Conveniently, the time it takes to detect the target analyte is very short. Thus, the devices and methods disclosed herein provide novel and useful means for point-of-care.

Disclosed herein is a biosensor for optical detection of Brownian relaxation dynamics of magnetic particles measured by light transmission. The magnetic particles can be functionalized with biological ligands for the detection of target analytes in a sample.

Some embodiments of the present disclosure are directed to systems and methods for separating, directing, and/or extracting a target molecule from a mix of molecules and may comprise a plurality of non-magnetic beads suspended in a ferro fluid, where the non-magnetic beads may be functionalized with at least one predetermined first molecule configured to bind with a target particle. A microfluidic device may be included which may comprise at least one microfluidic channel, the device configured to dynamically and/or statically receive an amount of the mix. Magnetic field means may be included and may be configured to apply a magnetic field to at least a portion of the at least one channel to exert an indirect force on the non-magnetic heads in the ferro fluid mix, and separate the non-magnetic beads from the ferrofluid. The beads may then be directed to at least one receptor region. At least one outlet may be provided which is arranged to be in communication with the at least one microfluidic channel, the at least one outlet may be configured to receive and extract the separated non-magnetic beads from the ferrofluid.

The invention discloses a method for selecting cells depending on their level of displaying and preferably secreting a protein of interest from a population of heterogeneously expressing cells, comprising: (a) contacting said cells with magnetic beads coated with an affinity group to the said cells, (b) mixing the said magnetic beads with the cells to capture the cells displaying/secreting the protein of interest, (c) performing at least one washing step to remove the non-captured cells, and (d) recovering the cells to which that magnetic beads have bound.

Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or moderate, severe, or moderate to severe traumatic brain injury (TBI), using cTnI. Also disclosed are methods for determining whether to perform a head computerized tomography on a subject by detecting levels of cTnI. Finally, also disclosed are methods of outcome in subjects suffering from a mild TBI.

The invention relates to a microplate, an in vitro diagnostic kit for HPV type 16 E7 oncoprotein detection and a preparation method thereof The in vitro diagnostic kit is comprised of a microplate pre-coated with an HPV type 16 E7 antibody and an HRP-labeled HPV type 16 E7 antibody with concentration of 0.05-0.4 μg/ml, wherein the amount of the antibody in each microwell of the microplate is 0.05-0.5 μg. The in vitro diagnostic kit is used for directly detecting the expression of high-risk HPV-associated oncoprotein and the expression level, and thus has a clear judgment on the infection degree of high-risk HPV, and facilitates subsequent treatment.

A system and method wherein components of a reagent such as labeled antibodies are separated from a biologically active sensor surface by depositing the reagent on a carrier surface distinct from a sensor surface in a detection region. The present device provides a short, well-defined and controlled, pre-incubation time between the particles of interest in the sample fluid and the reagent, thereby increasing the reproducibility by providing all components in one detection region such as a detection chamber.

The present disclosure provides methods and/or kits for detecting an analyte in a sample. Some embodiments provide a method for detecting a non-nucleic acid analyte in a sample using a solid substrate comprising a bound immobilisation agent and an antibody capture agent and a detectable agent, which can bind to the analyte. The antibody capture agent comprises, at a plurality of sites, a ligand for the immobilisation agent. A complex between the analyte, the antibody capture agent and a detectable agent is formed and immobilised on the solid substrate by binding between the immobilisation agent and the ligand. In some embodiments, the ligand and the immobilisation agent are a binding pair comprising a peptide tag and an anti-peptide tag antibody.